Format

Send to

Choose Destination
Med Oncol. 2019 Oct 8;36(11):93. doi: 10.1007/s12032-019-1318-5.

nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.

Author information

1
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
2
Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.
3
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
4
Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA.
5
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
6
Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.
7
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. dadkins@wustl.edu.
8
Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA. dadkins@wustl.edu.
9
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. dadkins@wustl.edu.

Abstract

In patients with locally advanced human papillomavirus (HPV)-unrelated head and neck squamous-cell carcinoma (HNSCC), cisplatin and radiation therapy (CisRT) resulted in a local-regional recurrence (LRR) rate of 35%, progression-free survival (PFS) of 49%, and overall survival (OS) of 60%. We, and others, showed that nab-paclitaxel is an active agent in metastatic and locally advanced HNSCC. The aim of this report was to assess the efficacy of nab-paclitaxel-based induction chemotherapy and CisRT in HPV-unrelated HNSCC. We performed a retrospective single-institution analysis of patients treated with nab-paclitaxel-based chemotherapy and CisRT. Key inclusion criteria included stage III-IV HPV-unrelated HNSCC. Induction chemotherapy included nab-paclitaxel and cisplatin (AP), AP + 5-fluorouracil (APF), or APF + Cetuximab (APF-C). Endpoints included LRR, overall relapse, PFS, and OS. Thirty-eight patients were the subject of this analysis. Patient characteristics included median age 59 years (IQR: 54-64) and smoking history in 36 patients (95%). Primary tumor sites included larynx/hypopharynx (27), p16 negative oropharynx (10), and oral cavity (1). Most patients had bulky disease: 82% T3-4 (n = 31) and 74% N2b-3 (n = 28). Median follow-up was 44 months (IQR: 23-59). The three-year LRR rate was 16% (95% confidence interval [CI] 7-34) and the overall relapse rate was 22% (95% CI 11-41). The three-year PFS was 64% (95% CI 46-77) and OS was 72% (95% CI 54-84). Among patients with HPV-unrelated HNSCC, nab-paclitaxel-based induction chemotherapy and CisRT resulted in a lower-than-expected rate of LRR and more favorable PFS and OS compared to historical results with CisRT.

KEYWORDS:

Cisplatin; HPV-unrelated; Head and neck cancer; Radiation; nab-Paclitaxel

PMID:
31595355
DOI:
10.1007/s12032-019-1318-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center